This refresh
Data-driven refresh July 19, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,233 tickers); 1,776 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.3
Health Information Services · price $21.52 · 1Y $24.56 · 5Y $35.95 · 10Y $53.33
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.0x B+ · PEG 0.59 A-
Why now. Doximity’s AI‑powered workflow assistant Ask is cementing the platform as the go‑to clinical knowledge hub, driving a virtuous loop of higher engagement and premium ad pricing. The business is growing revenue at 13.1% YoY while delivering a 30.4% profit margin and a stellar 20.6% ROE, giving the company a high‑quality growth engine that can compound earnings for years. The thesis rests on the continued expansion of the physician network and monetization of AI‑enhanced content, which should keep free‑cash‑flow growth well above the 3% implied by the reverse‑DCF.
Moat. The platform’s network of U.S. physicians creates a lock‑in effect: clinicians rely on the personalized newsfeed, clinical discussions, and the HIPAA‑compliant Ask assistant for daily decision‑making, making switching costly. This deep‑penetration lets Doximity command pricing power, reflected in its >30% margin and a >20% ROE, while competitors cannot quickly replicate the trusted data‑security and integrated workflow stack.
Risk. At a forward P/E of 22 the stock is priced for near‑term growth, yet the Bull Rankings model’s reverse‑DCF assumes only ~3% annual free‑cash‑flow growth—far below the 13.1% revenue expansion, suggesting optimism is already baked in. A slowdown in physician adoption of AI tools or a shift to competing platforms would compress margins and could push the stock back toward its 52‑week low of $17.15, confirming the bear case.
Horizon. 1-3 yr $24.56 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $35.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $53.33 if current growth sustains into durable earnings power.
2. HRMY — Harmony Biosciences Holdings, Inc. · score 89.4
Biotechnology · price $33.77 · 1Y $44.91 · 5Y $65.75 · 10Y $97.54
FCF $342m C · Rev +20.7% A- · D/E 0.18 B+ · P/E 13.6x A- · PEG 0.63 A-
Why now. The bull case hinges on WAKIX’s monopoly in narcolepsy‑related excessive daytime sleepiness, a rare‑neurology niche where the drug’s novel mechanism commands premium pricing. The business backs this with a 16.2% profit margin, a 20.7% YoY revenue growth and a PE of 13.6x, all while trading at a 31% discount to the analyst consensus target of $44.91. The thesis rests on compounding cash flow from expanding indications – PWS, Myotonic Dystrophy and high‑dose formulations – that will keep the growth pillar of our Bull Rankings model (score 100) alive.
Moat. WAKIX’s patented mechanism and FDA‑approved status create a high switching cost for patients and neurologists, effectively locking in a captive U.S. rare‑disease market. The company’s 16% ROE reflects pricing power derived from being the sole commercial‑stage provider in this segment, and its low debt‑to‑equity of 0.18 lets it reinvest cash without dilution, reinforcing the moat.
Risk. The bear case centers on the reverse‑DCF signal: the current price embeds an implied -20% annual free‑cash‑flow trajectory for the next decade, starkly at odds with the 20.7% revenue growth and a modest 13.6x PE that may already price in aggressive expansion. A setback in Phase 3 PWS or Phase 2 DM1 trials would crush the pipeline upside, and a PE above 13 could appear stretched if margin pressure rises, confirming the downside.
Horizon. 1-3 yr $44.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $65.75 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $97.54 if current growth sustains into durable earnings power.
3. ADBE — Adobe Inc. · score 89.3
Software - Application · price $237.25 · 1Y $272.48 · 5Y $398.93 · 10Y $591.79
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 13.6x A- · PEG 0.65 A-
Why now. Adobe's subscription‑driven Creative Cloud in the Digital Media segment is still expanding at 11.5% YoY revenue growth, fueling a 28.7% profit margin that translates into a staggering 62.8% ROE. Coupled with a low PEG of 0.65, the business compounds earnings faster than peers, and the Bull Rankings model’s 89.3 quality‑growth score—anchored by its strongest pillar, Quality—confirms the durability of this growth engine. The thesis rests on continued adoption of Adobe’s integrated creative suite by marketers, designers, and enterprises.
Moat. Adobe’s moat derives from the entrenched subscription ecosystem across its Digital Media and Digital Experience segments, where customers lock in multi‑year contracts for Photoshop, Premiere, and Experience Cloud tools. This creates high switching costs and a recurring‑revenue moat that underpins the 62.8% ROE, driven by pricing power in a category‑lead position that competitors struggle to replicate quickly.
Risk. The bear case centers on the market pricing in optimism: the reverse DCF shows the current price implies a negative -2% annual free‑cash‑flow growth over the next decade, yet revenue is only growing at 11.5% and the stock trades at a forward‑looking P/E of 13.6 with a beta of 1.43, exposing it to market volatility. A slowdown in subscription renewals or a rise in debt‑to‑equity to 0.61 could force the valuation lower, confirming the risk if growth decelerates.
Horizon. 1-3 yr $272.48 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $398.93 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $591.79 if current growth sustains into durable earnings power.
4. DLO — DLocal Limited · score 89.1
Software - Infrastructure · price $14.48 · 1Y $17.85 · 5Y $26.13 · 10Y $38.77
FCF $413m C · Rev +46.6% A · D/E 0.20 B+ · P/E 22.6x B+ · PEG 0.49 A
Why now. DLocal’s cross‑border pay‑in platform for e‑commerce, streaming and ride‑hailing merchants is a growth engine that is still scaling at 46.6% YoY revenue growth, fueling a free‑cash‑flow generation of $413 m and delivering an elite ROE of 34.6%. The Bull Rankings model gives the name a Quality‑Growth score of 89.1, with Growth as the strongest pillar, confirming that the business compounds earnings faster than peers. The thesis rests on the persistence of this high‑velocity payment‑processing tailwind.
Moat. The platform’s ability to accept hundreds of local cards, bank transfers and alternative payment methods creates deep integration with merchants and a costly switching hurdle, while the “dLocal for Platforms” suite locks in recurring volume from large digital ecosystems. This stickiness underpins the 34.6% ROE, which stems from pricing power in a fragmented emerging‑market payments landscape that rivals cannot replicate quickly.
Risk. The market is pricing DLocal at a forward P/E of 22.6, yet our reverse‑DCF shows the current price implies a negative ~7% annual free‑cash‑flow growth for the next decade—far below the 46.6% revenue surge, suggesting optimism may be overstated. Dilution of shareholders and a modest debt‑to‑equity of 0.2 add pressure, and any slowdown in cross‑border e‑commerce spend would immediately test the valuation. A sustained drop in revenue growth below the current 46.6% would confirm the bear case.
Horizon. 1-3 yr $17.85 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.13 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $38.77 if current growth sustains into durable earnings power.
5. INTU — Intuit Inc. · score 88.6
Software - Application · price $291.09 · 1Y $473.68 · 5Y $693.52 · 10Y $1,029
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 17.8x A- · PEG 0.77 A-
Why now. Intuit’s QuickBooks and Mailchimp platforms are fueling a 15.1% YoY revenue growth while delivering a 21.9% profit margin and generating $7.8B of free cash flow, all at a modest PE of 17.8x. Our Bull Rankings model rates the company 88.6/100 on quality‑growth, with Growth as the strongest pillar, underscoring a high‑quality compounder that can keep reinvesting cash into expanding the SMB ecosystem. The thesis hinges on the continued roll‑up of small‑ and mid‑market businesses into QuickBooks Online, compounding earnings at double‑digit rates.
Moat. Intuit’s moat lives in the sticky ecosystem of QuickBooks and its integrated payroll, payments, and financing services, which lock in SMB customers through data‑driven workflow automation and high switching costs. The 22.2% ROE reflects pricing power derived from being the de‑facto accounting platform for millions of U.S. businesses, a position competitors can’t replicate quickly without massive integration effort.
Risk. The biggest headwind is the premium valuation implied by a PE of 17.8x and a reverse‑DCF that assumes a -6% annual free‑cash‑flow growth for a decade, far below the 15.1% revenue expansion the business is actually delivering. If growth stalls or margin pressure mounts, the stock could tumble toward its 52‑week low of $252.84, confirming the bear case that the market has over‑priced future performance.
Horizon. 1-3 yr $473.68 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $693.52 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $1,029 if current growth sustains into durable earnings power.
6. NBIX — Neurocrine Biosciences, Inc. · score 87.3
Drug Manufacturers - Specialty & Generic · price $170.88 · 1Y $200.24 · 5Y $293.17 · 10Y $434.89
FCF $831m C+ · Rev +28.6% A- · D/E 0.14 B+ · P/E 26.3x B · PEG 0.48 A
Why now. The bull case hinges on NBIX’s dominant position in niche neurological and endocrine markets, anchored by INGREZZA for tardive dyskinesia and Orilissa for endometriosis, which together fuel a 28.6% YoY revenue growth and a healthy 21.6% profit margin. Our Bull Rankings model awards NBIX a perfect Growth pillar score of 100, underscoring the durability of its compounding earnings, while the PEG of 0.48 signals that the market is underpricing this growth. The thesis rests on the continued expansion of these specialty franchises and the ability to reinvest free cash flow ($831 m) into pipeline advancement.
Moat. NBIX’s moat derives from FDA‑approved, high‑margin specialty drugs that serve small, well‑defined patient populations, creating pricing power and low substitution risk. The company’s ROE of 19.6% reflects this pricing leverage, while a modest debt‑to‑equity of 0.14 and a beta of 0.39 give it financial flexibility that competitors in the crowded biotech space lack.
Risk. The bear case centers on the concentration of revenue in a handful of products—INGREZZA, Orilissa, Oriahnn and CRENESSITY—making NBIX vulnerable to competitive launches or adverse safety data that could erode its 21.6% profit margin. A forward P/E of 26.3 is elevated for a specialty biotech, implying that any slowdown from the current 28.6% revenue growth would trigger a sharp re‑rating. A breach in any of these key franchises would confirm the downside risk.
Horizon. 1-3 yr $200.24 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $293.17 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $434.89 if current growth sustains into durable earnings power.
7. LRN — Stride, Inc. · score 86.7
Education & Training Services · price $87.32 · 1Y $100.42 · 5Y $147.02 · 10Y $218.10
FCF $414m C · Rev +10.9% B · D/E 0.33 A- · P/E 13.7x A- · PEG 0.49 A
Why now. Stride’s integrated virtual‑school platform is rapidly becoming the default solution for districts seeking blended learning, and that stickiness fuels a compounding revenue engine. The business posted 10.9% FY revenue growth, translates into a healthy 12.2% profit margin and generated $414 m of free cash flow on a $3.7 b market cap, delivering an 18.8% ROE that outpaces most education peers. With a low‑beta (0.1) and a modest debt‑to‑equity of 0.33, the upside hinges on continued enrollment expansion in the virtual‑school segment, which should keep the free‑cash‑flow trajectory positive and compound earnings for years to come.
Moat. The moat lives in Stride’s end‑to‑end suite for virtual and blended public schools – from enrollment software to curriculum delivery – creating high switching costs for districts that have invested in the platform’s data and workflow integration. This deep integration underpins the 18.8% ROE, as schools are willing to pay a premium for a proven, turnkey solution that no new entrant can replicate quickly.
Risk. The bear case centers on the price’s implicit assumption of a –9% annual free‑cash‑flow decline over the next decade, which is at odds with the current 10.9% revenue growth and could be exposed if state education budgets tighten or if competing ed‑tech platforms win district contracts. A slowdown in enrollment or margin compression would validate the over‑optimistic valuation and push the stock back toward its 52‑week low of $60.61. The key trigger for the downside is a material dip in FY revenue growth coupled with margin erosion.
Horizon. 1-3 yr $100.42 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $147.02 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $218.10 if current growth sustains into durable earnings power.
8. NVDA — NVIDIA Corporation · score 86.6
Semiconductors · price $202.81 · 1Y $302.31 · 5Y $442.61 · 10Y $656.59
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 31.1x B · PEG 0.56 A-
Why now. The bull case hinges on NVIDIA's Compute & Networking segment powering the AI data‑center boom, where its accelerated computing platforms are now the de‑facto standard. Our model awards a Quality‑Growth score of 86.6 (Growth pillar 100, Value pillar 74), and the strongest pillar—Growth—means the business is delivering 70.7% YoY revenue growth while maintaining a 63% profit margin, fueling a free‑cash‑flow engine that the reverse‑DCF implies must grow ~48% per year for a decade. The thesis rests on the persistence of AI‑driven demand in data centers, which will keep compounding earnings at a rate far above the market’s 31.1× P/E.
Moat. NVIDIA’s moat derives from its proprietary GPU architecture and software stack that lock in hyperscale cloud providers and enterprise AI customers, creating massive switching costs. The 81.7% ROE reflects pricing power from category leadership in AI‑accelerated computing, where rivals cannot match the integrated hardware‑software ecosystem without years of R&D and massive capital outlays.
Risk. The bear case centers on the lofty valuation—PE of 31.1× and a beta of 2.21—making the stock vulnerable to a market pull‑back or a slowdown in AI spending that would force revenue growth to decelerate below the 48% FCF growth baked into the price. A dip in the data‑center segment or a successful alternative from a competitor would compress margins and could see the price retreat toward the 52‑week low of 164.07. Confirmation of the bear case would be a quarterly revenue growth slowdown to single‑digit percentages.
Horizon. 1-3 yr $302.31 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $442.61 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $656.59 if current growth sustains into durable earnings power.
9. EXLS — ExlService Holdings, Inc. · score 85.4
Information Technology Services · price $28.16 · 1Y $40.13 · 5Y $58.75 · 10Y $87.15
FCF $297m C · Rev +13.4% B+ · D/E 0.67 C+ · P/E 17.9x A- · PEG 0.90 B+
Why now. EXLS is a high‑margin AI‑driven claims and underwriting platform that is rapidly expanding across Insurance and Banking, delivering 13.4% YoY revenue growth, a stellar ROE of 32.3% and a free‑cash‑flow generation of $297 m. Our Bull Rankings model rates its Growth pillar at 91 – the strongest of the three – confirming that the compounding engine in digital operations is far from exhausted, and the market is pricing in a pessimistic -1% FCF growth over the next decade. The thesis rests on the continuation of AI‑enabled automation winning deeper contracts in the insurance‑tech space, which will keep the earnings multiple expanding toward the analyst consensus target of $40.13.
Moat. EXLS’s moat lies in its end‑to‑end AI workflow that handles claims management, policy servicing and actuarial analytics for large insurers, creating high switching costs because clients embed the platform into core loss‑adjustment processes. The 32.3% ROE is driven by pricing power in a niche where few competitors can match its data‑rich models, and the company’s buy‑back program further entrenches shareholder value while limiting dilution.
Risk. The bear case centers on the modest valuation premium: a forward P/E of 17.9 is above the sector average and the model’s Value pillar scores only 81, indicating the stock may be over‑priced relative to its cash‑flow outlook. A slowdown in insurance spend or a loss of a major client could compress the 11.7% profit margin, and the 0.67 debt‑to‑equity ratio leaves limited headroom for aggressive expansion. A breach of the 52‑week low at $24.85 would confirm that the market’s optimism is misplaced.
Horizon. 1-3 yr $40.13 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $58.75 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $87.15 if current growth sustains into durable earnings power.
10. ADMA — ADMA Biologics, Inc. · score 84.5
Biotechnology · price $8.71 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $108m C · Rev +11.0% B · D/E 1.11 C · P/E 12.8x A · PEG 0.65 A-
Why now. The bull case hinges on ADMA’s dominant position in the IVIG market, where BIVIGAM and ASCENIV together capture the growing demand for primary humoral immunodeficiency therapy. Our model awards a Quality‑Growth score of 84.5 with Growth as the strongest pillar, underscoring a 11% FY revenue growth and a stellar 32.4% profit margin. Coupled with a low beta of 0.73, the compounding engine is the expanding IVIG sales base, which should keep earnings accelerating well beyond the modest 3% annual free‑cash‑flow growth implied by the reverse‑DCF.
Moat. ADMA’s moat stems from its integrated plasma‑collection and bio‑manufacturing platform, which secures a reliable source of high‑quality plasma for BIVIGAM and ASCENIV—products that hospitals rely on for life‑saving immunodeficiency treatment. This vertical integration yields a ROE of 42.4%**, reflecting pricing power and cost advantage that rivals cannot quickly replicate without building costly collection networks.
Risk. The bear case focuses on the high debt load, with a debt‑to‑equity of 1.11**, and a PE of 12.8**, suggesting the market may be pricing in slower growth or margin compression if competitive IVIG biosimilars erode pricing power. A breach of the 52‑week low ($7.21) or a widening of the debt ratio would confirm the risk and invalidate the growth narrative.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
11. CARG — CarGurus, Inc. · score 83.5
Auto & Truck Dealerships · price $35.00 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +14.0% B+ · D/E 0.79 B · P/E 18.4x B+ · PEG 1.06 B+
Why now. CarGurus’ Digital Deal platform is unlocking a new, high‑margin revenue stream by letting shoppers start purchases online, and that engine is super‑charged by its 14% YoY revenue growth, a stellar 15.9% profit margin and a PE of 18.4x that still leaves room for upside. Our Bull Rankings model gives CARG an 83.5/100 quality‑growth score, with Quality as the strongest pillar, underscoring the durability of its dealer‑subscription moat. The thesis rests on the compounding power of Digital Deal expanding across the U.S. and international markets, driving earnings to keep accelerating.
Moat. The moat lives in CarGurus’ integrated dealer subscription and advertising ecosystem, which locks dealers into a data‑rich marketplace where they pay for leads and brand exposure. This network effect yields an ROE of 62.9%, a direct result of pricing power from being the go‑to platform for both large dealer groups and independent lots, making it costly for rivals to replicate the depth of inventory and shopper traffic.
Risk. The bear case centers on the valuation stretch: a PE of 18.4x is high for a growth name, and the Bull Rankings model’s reverse DCF implies a negative free‑cash‑flow growth of about -1% annually for the next decade—far below the actual 14% revenue growth, suggesting optimism may already be baked in. A slowdown in Digital Deal adoption or a rise in debt‑to‑equity above the current 0.79 would trigger a re‑rating, and a breach of the 52‑week low ($26.39) would confirm the downside.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
12. RMD — ResMed Inc. · score 83.2
Medical Instruments & Supplies · price $198.99 · 1Y $249.40 · 5Y $365.15 · 10Y $541.67
FCF $1.8b C+ · Rev +10.3% B · D/E 0.13 B+ · P/E 19.2x A- · PEG 1.18 B+
Why now. ResMed’s dominant position in cloud‑connected sleep diagnostics – exemplified by its ApneaLink Air and NightOwl devices – fuels a virtuous cycle of recurring software revenue and high‑margin hardware sales. The business is growing revenue at 10.3% YoY, converting that into a stellar 27.4% profit margin and a robust ROE of 23.4%, which the Bull Rankings model rewards with a Quality‑growth score of 83.2 (Quality pillar 90). This compounding engine, anchored by a 0.13 debt‑to‑equity ratio and a low beta of 0.78, promises continued cash generation, making the current price a bet on sustained growth rather than a value discount.
Moat. The moat lies in ResMed’s integrated hardware‑software ecosystem for sleep and breathing health, where devices like ApneaLink Air feed data into proprietary cloud platforms that clinicians rely on for diagnosis and therapy titration. This creates high switching costs for hospitals and home‑care providers, locking in recurring subscription revenue and enabling pricing power that underpins the 23.4% ROE, far above sector averages.
Risk. The bear case centers on the premium valuation: a forward P/E of 19.2 implies investors are pricing in growth far beyond the historical 10.3% revenue expansion, especially when the reverse DCF suggests only ~1% annual free‑cash‑flow growth over the next decade. Any slowdown in device adoption or margin compression would expose this optimism, and a rise in debt‑to‑equity above the current 0.13 could trigger a sell‑off. A sustained miss on quarterly revenue growth would confirm the overvaluation thesis.
Horizon. 1-3 yr $249.40 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $365.15 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $541.67 if current growth sustains into durable earnings power.
13. EPAM — EPAM Systems, Inc. · score 83
Information Technology Services · price $88.66 · 1Y $135.94 · 5Y $199.03 · 10Y $295.25
FCF $544m C+ · Rev +14.2% B+ · D/E 0.08 B+ · P/E 12.7x A · PEG 0.46 A
Why now. EPAM’s digital platform engineering franchise is poised to compound revenue at 14.2% YoY while delivering free cash flow of $544 m and a modest P/E of 12.7×, a rare blend of growth and cash generation that fuels our Bull Rankings model’s 83/100 quality‑growth score. The Bull case rides the cloud‑services and AI‑analytics segments where enterprise clients lock in multi‑year engineering contracts, ensuring the growth engine persists. The thesis hinges on the ability to keep expanding the high‑margin services portfolio faster than the market expects.
Moat. EPAM’s moat lives in its end‑to‑end engineering platform that couples requirements analysis, cloud migration, and AI‑driven analytics into a single, highly integrated offering, creating deep switching costs for large enterprise customers who embed EPAM’s code and processes across critical systems. This integration, combined with a low debt‑to‑equity of 0.08, lets the firm reinvest cash without diluting shareholders, reinforcing its pricing power in the high‑growth digital transformation market.
Risk. The bear case centers on the premium valuation implied by the reverse‑DCF – a -3% annual free‑cash‑flow growth assumption that far outpaces the realistic revenue growth of 14.2%, meaning any slowdown or margin compression would expose the stock to a sharp correction. A beta of 1.43 amplifies market volatility, and a P/E of 12.7, while low, may already price in the optimistic growth trajectory; a miss on the next revenue quarter would trigger a sell‑off and invalidate the bull thesis.
Horizon. 1-3 yr $135.94 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $199.03 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $295.25 if current growth sustains into durable earnings power.
14. IT — Gartner, Inc. · score 82.5
Information Technology Services · price $140.19 · 1Y $162.46 · 5Y $237.86 · 10Y $352.85
FCF $1.3b C+ · Rev +2.3% C · D/E n/a · P/E 13.9x A- · PEG 0.58 A-
Why now. Gartner’s Insights subscription model is a cash‑machine, delivering $1.3B of free cash flow on a modest 11.4% profit margin while still growing revenue at +2.3% YoY. The subscription base across North America, Europe, and APAC creates recurring, low‑churn income that compounds each year, and the current price already embeds a -14% annual free‑cash‑flow growth assumption from our reverse‑DCF, making the upside tied to sustaining even modest top‑line growth. The thesis rests on the ability to keep expanding the Insights subscriber universe and leverage the high‑quality moat.
Moat. The Insights segment’s subscription‑based access to proprietary data, benchmarks, and a network of technology experts creates a high switching cost for enterprise clients that rely on Gartner’s research for strategic decisions. This entrenched relationship, combined with the Conferences segment’s unique peer‑driven events, locks in multi‑year contracts and limits competitors’ ability to replicate the depth of Gartner’s content ecosystem.
Risk. The bear case centers on the slowing revenue growth of only 2.3% YoY, which is well below the sector’s average and raises concerns that Gartner’s subscription base may be saturating. Coupled with a relatively elevated P/E of 13.9 for a low‑growth business, any further deceleration or margin compression could force the stock toward its 52‑week low of $124.25. A sustained miss on revenue growth would confirm the downside and invalidate the bull thesis.
Horizon. 1-3 yr $162.46 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $237.86 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $352.85 if current growth sustains into durable earnings power.
15. VEEV — Veeva Systems Inc. · score 82
Health Information Services · price $195.38 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 34.6x C+ · PEG 0.88 B+
Why now. Veeva’s Vault CRM Suite locks pharmaceutical and biotech giants into a single, cloud‑native workflow, driving a 16.2% YoY revenue growth while delivering a 28.4% profit margin that fuels a free‑cash‑flow generation of $1.7B. Our Bull Rankings model rates the company 82/100 on Quality‑Growth, with Growth as the strongest pillar, underscoring the durability of this compounding engine. The thesis hinges on Veeva’s ability to keep expanding its Commercial Cloud across every major life‑sciences market, turning each new client into a long‑term, high‑margin revenue stream.
Moat. The Vault platform creates a data‑rich, regulatory‑compliant ecosystem that is prohibitively costly for customers to replace, giving Veeva deep switching costs and network effects across its CRM, PromoMats, and Data Cloud solutions. This stickiness translates into a ROE of 12.9%—well above the sector average—because Veeva can command premium pricing for a suite that no competitor can replicate quickly.
Risk. At a forward P/E of 34.6 the market is pricing in growth far above the historical 16.2% revenue expansion, and the Bull Rankings model flags Value as the weakest pillar, suggesting the current price may be stretched. A slowdown in life‑sciences spending or a successful win by a rival cloud provider would force the valuation down, with the PEG ratio of 0.88 turning into a red flag. The bear case is confirmed if revenue growth falls below 16.2% and the 8% implied FCF growth from the reverse DCF looks unattainable.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
16. PRDO — Perdoceo Education Corporation · score 81.2
Education & Training Services · price $31.66 · 1Y $36.41 · 5Y $53.31 · 10Y $79.08
FCF $225m C · Rev +17.7% B+ · D/E 0.12 A- · P/E 12.1x A- · PEG 0.69 A-
Why now. The Bull Rankings model gives PRDO a Quality‑growth score of 81.2, anchored by a Quality pillar of 89 – the strongest among peers – because its Colorado Technical University and AIU segments dominate career‑oriented online education, delivering 17.7% YoY revenue growth, a 19.9% profit margin and $225 m of free cash flow. This high‑margin, cash‑rich engine fuels a sustainable compounding loop as more students enroll in high‑demand fields like nursing and cybersecurity, and the thesis hinges on the continuation of this growth trajectory.
Moat. PRDO’s moat lies in its integrated online‑learning platform and accredited degree pathways across CTU, AIU and USAHS, which lock in students seeking fast‑track, career‑focused credentials; the blend of online delivery and niche health‑science programs creates switching costs and a pipeline of repeat enrollments, while the 17% ROE reflects pricing power from being a leading provider in these specialized tracks.
Risk. The bear case centers on the Bull Rankings model’s reverse‑DCF, which implies a -15% annual free‑cash‑flow growth for the next decade – a stark contrast to the current 17.7% revenue expansion, meaning the market is pricing in overly optimistic growth; a slowdown in enrollment or tighter federal funding could force the FCF growth to align with the -15% assumption, crushing the upside and validating a lower valuation.
Horizon. 1-3 yr $36.41 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $53.31 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $79.08 if current growth sustains into durable earnings power.
17. APP — AppLovin Corporation · score 80.5
Advertising Agencies · price $424.54 · 1Y $654.60 · 5Y $958.40 · 10Y $1,422
FCF $4.4b B · Rev +66.4% A · D/E 1.63 C · P/E 36.9x C+ · PEG 1.17 B+
Why now. The bull case hinges on MAX, AppLovin's AI‑driven in‑app bidding platform, which is scaling with the explosive 66.4% FY revenue growth and is underpinned by a 64.3% profit margin that translates into robust cash generation; the model’s $4.4B free cash flow gives the company a high‑yield growth engine that can be reinvested into the bidding technology. Combined with a PE of 36.9 that still reflects a premium for growth, the thesis rests on the continuation of this compounding cycle.
Moat. MAX creates a durable moat through real‑time competitive auctions that lock publishers into a high‑margin, data‑rich ecosystem, while Adjust’s measurement suite deepens stickiness with developers who rely on precise attribution. The AI‑powered ad stack raises switching costs because advertisers gain incremental ROI only by staying within AppLovin’s integrated platform, a capability hard to replicate quickly.
Risk. The bear case centers on the lofty valuation: a PE of 36.9 and a beta of 2.48 imply that any slowdown in revenue growth or a margin squeeze would cause outsized price volatility, especially given the debt‑to‑equity of 1.63 that could limit flexibility in a tightening credit environment. A breach of the 52‑week low ($343) would signal that the market is pricing in a growth deceleration, eroding the bull thesis.
Horizon. 1-3 yr $654.60 (analyst consensus (n=30)) — fundamentals + valuation re-rating. 5 yr $958.40 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $1,422 if current growth sustains into durable earnings power.
18. DXCM — DexCom, Inc. · score 80.5
Medical Devices · price $76.65 · 1Y $85.75 · 5Y $125.55 · 10Y $186.24
FCF $1.4b C+ · Rev +16.1% B+ · D/E 0.47 B · P/E 32.9x B · PEG 1.45 B
Why now. DexCom’s G7 platform is rapidly winning over both Type 1 and insulin‑using Type 2 diabetics, driving a 16.1% YoY revenue growth and a 19.3% profit margin that fuels a 31.5% ROE. Our Bull Rankings model awards DXCM an 80.5 quality‑growth score, with Growth as the strongest pillar, confirming that the business’s compounding earnings are sustainable. The thesis rests on continued market share gains in the CGM space, which should keep the growth engine humming.
Moat. DXCM’s moat stems from its integrated CGM ecosystem—Dexcom G7, G7 15 Day, Dexcom ONE+, and the Share/Follow apps—locked into endocrinologists and diabetes clinics that require FDA‑cleared, clinically validated sensors. High switching costs and the proprietary algorithm that translates raw glucose data into actionable insights give the company pricing power, reflected in its 31.5% ROE, and make it hard for rivals to replicate the full stack quickly.
Risk. The bear case focuses on the premium valuation: a forward P/E of 32.9 is well above the sector average, and the Bull Rankings model flags Value as its weakest pillar, suggesting the stock may be over‑priced if growth slows. A slowdown in new‑patient adoption or aggressive pricing from competitors could compress margins, and a breach of the 0.47 debt‑to‑equity threshold would amplify financial risk. Confirmation of the bear case would be a quarterly earnings miss that forces the P/E below 30.
Horizon. 1-3 yr $85.75 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $125.55 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $186.24 if current growth sustains into durable earnings power.
19. META — Meta Platforms, Inc. · score 79.7
Internet Content & Information · price $646.01 · 1Y $822.69 · 5Y $1,204 · 10Y $1,787
FCF $48.3b A · Rev +26.2% A- · D/E 0.36 B+ · P/E 23.5x B · PEG 0.94 B+
Why now. Meta’s Family of Apps (FoA) is still compounding at a breakneck clip, delivering 26.2% YoY revenue growth and a 32.8% profit margin that fuels a massive $48.3B of free cash flow. The Bull Rankings model flags Growth as its strongest pillar (97) and our 79.7 quality‑growth score confirms the business is a high‑quality compounder. With a PEG of 0.94, the stock is priced for just‑under‑linear earnings expansion, making the upside hinge on FoA’s ability to keep monetizing its global user base.
Moat. Meta’s moat lives in the network effects of Facebook and Instagram, where each additional user makes the platform more valuable for advertisers, locking in a self‑reinforcing ad ecosystem. Its 29% ROE stems from pricing power as the go‑to venue for social commerce and video ads, a position rivals can’t replicate quickly because they lack the same depth of user data and cross‑app integration.
Risk. The bear case centers on the lofty reverse‑DCF assumption that free‑cash‑flow must grow ~30% annually for a decade—far above the current 26.2% revenue pace—making the stock vulnerable if FoA growth decelerates or Reality Labs drags cash flow. A P/E of 23.5 and beta of 1.25 signal market optimism and volatility; a miss on growth would push the valuation toward the lower end of the analyst range and trigger a sell‑off.
Horizon. 1-3 yr $822.69 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,204 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $1,787 if current growth sustains into durable earnings power.
20. MELI — MercadoLibre, Inc. · score 79.6
Internet Retail · price $1813.91 · 1Y $2,215 · 5Y $3,243 · 10Y $4,810
FCF $11.8b A- · Rev +36.4% A · D/E 1.70 C+ · P/E 47.8x C · PEG 1.12 B+
Why now. The bull case hinges on MercadoLibre’s unstoppable e‑commerce engine in Brazil and Mexico, driven by its Marketplace and the cash‑generating Mercado Pago suite. Revenue is exploding at 36.4% YoY, free cash flow sits at a massive $11.8 B, and ROE of 26.4% shows the business is turning that growth into shareholder returns. The combination of a 100‑point Growth pillar and a 79.6 overall quality‑growth score means the compounding engine will keep powering earnings well beyond the next year.
Moat. MELI’s moat lives in the tightly integrated Marketplace‑to‑Pago loop: sellers need Mercado Pago to accept payments, and buyers stay for the seamless checkout and fast Mercado Envios delivery. This network creates high switching costs for both merchants and consumers, while the 26.4% ROE reflects pricing power that stems from being the dominant platform in the region’s fragmented online retail landscape.
Risk. The bear case centers on an over‑inflated valuation – a forward PE of 47.8 versus peers and a reverse‑DCF that assumes a -7% annual free‑cash‑flow growth for the next decade, starkly below the 36.4% revenue growth we see today. A slip in growth or a widening debt‑to‑equity ratio of 1.7 would force the stock back toward its 52‑week low of $1,495, confirming the over‑optimism.
Horizon. 1-3 yr $2,215 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,243 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,810 if current growth sustains into durable earnings power.
21. PODD — Insulet Corporation · score 79.1
Medical Devices · price $164.06 · 1Y $238.22 · 5Y $348.77 · 10Y $517.38
FCF $416m C · Rev +31.9% A · D/E 0.78 C+ · P/E 38.3x C+ · PEG 1.45 B
Why now. The Omnipod 5 automated insulin delivery system is unlocking a new wave of subscription‑based, high‑margin revenue as diabetics shift from pump to patch, and Insulet’s 31.9% YoY revenue growth proves the market is responding. Our Bull Rankings model gives the stock a 79.1/100 quality‑growth score, with Growth as the strongest pillar, underscoring that the business is a genuine high‑quality compounder. Coupled with a 10.4% profit margin and 23.2% ROE, the compounding engine is the proprietary AID algorithm embedded in the Omnipod 5 pod – the thesis rests on that technology continuing to drive double‑digit top‑line expansion.
Moat. Insulet’s moat lives in the Omnipod platform’s patented AID algorithm and Bluetooth‑enabled pod, which lock patients into a seamless, wireless ecosystem that rivals can’t replicate without costly FDA pathways. The high ROE of 23.2% stems from pricing power derived from category leadership in patch‑based insulin delivery, and the integrated pod‑to‑CGM link creates a switching cost that keeps clinicians and patients tethered to Insulet’s ecosystem.
Risk. The stock trades at a lofty PE of 38.3x while the reverse‑DCF implies a 21% annual free‑cash‑flow growth rate—far above the 31.9% revenue growth pace, suggesting the market may be over‑optimistic. A debt‑to‑equity of 0.78 adds leverage risk if growth stalls, and a beta of 1.11 amplifies downside in a market pull‑back. A breach of the 52‑week low ($138.79) would confirm that the premium valuation is unsustainable.
Horizon. 1-3 yr $238.22 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $348.77 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $517.38 if current growth sustains into durable earnings power.
22. NFLX — Netflix, Inc. · score 78.7
Entertainment · price $68.95 · 1Y $97.91 · 5Y $143.35 · 10Y $212.64
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.47 B · P/E 21.7x B · PEG 1.35 B
Why now. Netflix’s global streaming franchise continues to compound on its unrivaled content library and device ubiquity, driving a relentless subscriber expansion that fuels cash generation. The business delivers 28.2% profit margin, $11.2B free cash flow and a 45.3% ROE, all while posting 16% revenue growth YoY—a growth rate the Bull Rankings model flags as far below the 27%/yr free‑cash‑flow growth baked into today’s price, indicating upside if the company sustains its high‑margin expansion. The thesis rests on Netflix’s ability to keep monetizing its ever‑growing content slate across every internet‑connected device, compounding earnings for the next decade.
Moat. Netflix’s moat lies in its massive, data‑driven content ecosystem that locks in members on a single platform across TVs, set‑top boxes and mobiles. Its 45.3% ROE stems from pricing power earned by being the default streaming choice for households worldwide, a position competitors can’t replicate quickly because of Netflix’s proprietary recommendation engine and deep library of originals that drive stickiness and reduce churn. The high‑margin subscription model also yields a free‑cash‑flow engine that funds continual content investment, reinforcing the cycle.
Risk. The bear case centers on the premium valuation implied by a P/E of 21.7 and a beta of 1.52, which together suggest the market expects growth far above the 16% revenue pace. Any slowdown—whether from intensified competition eroding subscriber acquisition or a rise in content costs that squeezes the 28.2% margin—would force the stock toward its 52‑week low of $65.08. A breach of the $70 lower analyst target range would confirm the downside, triggering a sell‑off as the price can no longer justify the growth premium.
Horizon. 1-3 yr $97.91 (analyst consensus (n=43)) — fundamentals + valuation re-rating. 5 yr $143.35 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $212.64 if current growth sustains into durable earnings power.
23. DECK — Deckers Outdoor Corporation · score 78.4
Footwear & Accessories · price $106.49 · 1Y $127.81 · 5Y $187.13 · 10Y $277.59
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 15.2x A- · PEG 1.33 B
Why now. The Bull Rankings model gives DECK a 78.4/100 quality‑growth score, with Quality as its strongest pillar, and the HOKA performance‑footwear franchise is now expanding at 9.8% revenue growth, delivering 18.7% profit margin and generating $1.1 B of free cash flow. Combined with a stellar 41% ROE and a modest 0.15 debt‑to‑equity ratio, the business compounds earnings at a rate that outpaces the reverse‑DCF implied 4% FCF growth, meaning the market is still pricing in a conservative outlook. The thesis rests on continued HOKA and UGG premium‑pricing momentum driving compounding returns.
Moat. DECK’s moat stems from the pricing power of its UGG and HOKA lines, which command premium prices in the casual‑lifestyle and high‑performance segments, allowing the company to sustain a 41% ROE. Its vertically integrated design‑to‑retail network, anchored by strong relationships with domestic and international retailers, creates switching costs for consumers who value the distinctive fit and technology of HOKA shoes and the iconic comfort of UGG boots—advantages that are hard for new entrants to replicate quickly.
Risk. The biggest risk is a slowdown in premium‑footwear demand that would erode the current 9.8% revenue growth, leaving the stock vulnerable given the reverse‑DCF assumption of only 4% FCF growth. A beta of 1.17 amplifies market volatility, and if growth falls below the model’s expectations, the 15.2 P/E multiple could become unjustified, prompting a sell‑off. Confirmation of the bear case would be a quarterly revenue miss paired with a margin contraction below the 18.7% historical level.
Horizon. 1-3 yr $127.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $187.13 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $277.59 if current growth sustains into durable earnings power.
24. FIVE — Five Below, Inc. · score 78.3
Specialty Retail · price $202.63 · 1Y $260.33 · 5Y $381.15 · 10Y $565.42
FCF $505m C+ · Rev +25.9% A- · D/E 0.86 B · P/E 25.6x C+ · PEG 0.98 B+
Why now. Five Below’s relentless expansion of its teen‑focused, low‑price lifestyle aisle—think novelty décor, loungewear and party goods—is fueling a revenue surge of 25.9% YoY while delivering a free‑cash‑flow haul of $505 m and a solid 19% ROE. Our Bull Rankings model crowns Growth as its strongest pillar (99) and the 78.3/100 quality‑growth score validates the compounding engine, while the reverse‑DCF implies a 13% FCF growth rate—well below the 25.9% sales pace—meaning the market already prices in optimism, leaving upside if the growth streak endures.
Moat. The moat lives in Five Below’s curated, high‑turnover assortment that captures price‑sensitive Gen‑Z shoppers who prefer a constantly refreshed “treasure‑hunt” experience, creating sticky foot traffic and low‑cost inventory turnover. This translates into a 19% ROE driven by pricing power in the value‑oriented specialty retail niche, a lever competitors struggle to replicate without similar scale and store footprint.
Risk. The bear case hinges on the company’s elevated valuation—PE of 25.6x and a PEG of 0.98—which assumes growth sustaining near its historical 25.9% clip; any slowdown, combined with a debt‑to‑equity of 0.86 and beta of 1, could compress margins and trigger a sell‑off. A breach of the 13% implied FCF growth threshold would confirm the risk and force the stock back toward its 52‑week low.
Horizon. 1-3 yr $260.33 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $381.15 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $565.42 if current growth sustains into durable earnings power.
25. MU — Micron Technology, Inc. · score 77.5
Semiconductors · price $848.95 · 1Y $1,492 · 5Y $2,184 · 10Y $3,240
FCF $26.2b A · Rev +167.0% A · D/E 0.06 A- · P/E 19.2x A- · PEG 0.12 A
Why now. Micron’s explosive 167% FY YoY revenue growth in its Cloud Memory and Core Data Center units is being fueled by the AI‑driven surge in high‑bandwidth memory demand, and the company is converting that top‑line expansion into a stellar 55.9% profit margin and a record 50.1% ROE. The combination of a $26.2B free‑cash‑flow engine and a market‑cap of under $1T gives the stock a rare growth‑at‑reasonable‑price profile that can compound as AI workloads expand. The thesis rests on the persistence of data‑center memory spend outpacing the broader semiconductor cycle.
Moat. Micron’s moat lies in its dominant position supplying high‑bandwidth and CXL‑based memory to hyperscale cloud providers—customers that face massive switching costs because redesigning data‑center architectures is capital‑intensive. This pricing power underpins the extraordinary 50.1% ROE and is reinforced by a rock‑solid balance sheet (debt‑to‑equity 0.06), making it difficult for rivals to erode margins without massive capex.
Risk. The stock is priced for a near‑term reality check: the Bull Rankings model’s reverse‑DCF assumes a 44% annual free‑cash‑flow growth for a decade, far above the already extreme 167% revenue surge and unsustainable in a maturing AI market. Coupled with a high beta of 2.14, any slowdown in data‑center spend or a pricing squeeze would quickly erode the 19.2× P/E, and a breach of the 52‑week low ($103.38) would signal the bear case materializing.
Horizon. 1-3 yr $1,492 (analyst consensus (n=42)) — fundamentals + valuation re-rating. 5 yr $2,184 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $3,240 if current growth sustains into durable earnings power.
26. YUMC — Yum China Holdings, Inc. · score 76.3
Restaurants · price $43.87 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +6.7% C+ · D/E 0.38 A- · P/E 16.8x B+ · PEG 1.10 B+
Why now. The bull case hinges on Yum China’s dominant KFC franchise network, which continues to capture urban diners and drive a 6.7% YoY revenue growth while generating $931 m of free cash flow and a solid 17.4% ROE. Our Bull Rankings model awards a Quality‑growth score of 76.3, with Quality as the strongest pillar, underscoring the brand’s operational excellence, and the stock trades at a low PE of 16.8x. The reverse‑DCF implies only ~5% annual FCF growth, well below the 6.7% revenue pace, meaning the market is already optimistic and the upside rests on scaling delivery and menu innovation across KFC and Pizza Hut.
Moat. Our model’s top Quality rating reflects Yum China’s entrenched KFC and Pizza Hut footprints in China’s densely populated cities, where localized menus and an integrated online delivery platform create high switching costs. This scale translates into pricing power that fuels a ROE of 17.4%, a level hard for new entrants to replicate without comparable real‑estate and supply‑chain depth.
Risk. The weakest Growth pillar (73) warns that revenue expansion is slowing, and the reverse‑DCF implied ~5% annual FCF growth exceeds the modest 6.7% revenue growth, suggesting optimism is already priced in. A sustained margin dip below the 7.8% profit margin or a rise in debt‑to‑equity would force the PE to compress, confirming the downside.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
27. FISV — Fiserv, Inc. · score 75.9
Sector n/a · price $50.63 · 1Y $67.37 · 5Y $98.64 · 10Y $146.32
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.6x A- · PEG 2.38 C
Why now. Our Bull Rankings model gives FISV a Quality‑growth score of 75.9, with Quality as the strongest pillar (82) and Value the weakest (68). The bull case hinges on the company’s high‑margin payments platform that continues to capture merchant spend, delivering 19.7% profit margin and $4.1B free cash flow while revenue still climbs 9.3% YoY. That combination of cash generation and double‑digit margin compounding fuels a sustainable earnings runway – the thesis rests on the persistence of this cash‑rich, high‑margin growth engine.
Moat. Fiserv’s moat stems from entrenched relationships with large financial institutions and merchants that rely on its integrated processing stack, creating switching costs that lock in recurring fee revenue. The platform’s scale yields a 12.2% ROE, reflecting pricing power derived from its position as a core payments infrastructure provider that competitors cannot replicate quickly without massive investment.
Risk. The bear case is that the market has baked in aggressive growth expectations: the reverse DCF shows the current price implies a -16% annual free‑cash‑flow growth rate for the next decade, far outpacing the actual 9.3% revenue growth. If growth stalls or margins compress, the stock could tumble from its 52‑week high of $167.39, confirming the over‑optimism and breaking the bull thesis.
Horizon. 1-3 yr $67.37 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $98.64 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $146.32 if current growth sustains into durable earnings power.
28. ULTA — Ulta Beauty, Inc. · score 75.1
Specialty Retail · price $479.57 · 1Y $623.58 · 5Y $912.99 · 10Y $1,354
FCF $1.1b C+ · Rev +11.3% B · D/E 0.89 B · P/E 18.0x B+ · PEG 1.67 C+
Why now. Specialty Retail · market cap $20.6b. Down 33% from 52-week high of $714.97 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.58 (implying +30% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 33% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $623.58 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.99 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
29. EME — EMCOR Group, Inc. · score 75
Engineering & Construction · price $744.16 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +18.3% B+ · D/E 0.13 A- · P/E 25.0x B+ · PEG 0.40 A
Why now. Engineering & Construction · market cap $33.1b. Down 22% from 52-week high of $951.96 — deep drawdown territory. Revenue growing +18%, comfortably above the S&P median. PEG 0.40 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,000 (implying +34% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~11% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
30. DEO — Diageo plc · score 74.1
Beverages - Wineries & Distilleries · price $84.00 · 1Y $101.14 · 5Y $148.08 · 10Y $219.67
FCF n/a · Rev +4.8% C+ · D/E 1.77 C+ · P/E 19.4x B · PEG 0.84 B+
Why now. Beverages - Wineries & Distilleries · market cap $46.7b. Down 28% from 52-week high of $116.41 — deep drawdown territory. PEG 0.84 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $101.14 (implying +20% upside).
Moat. Net margin 16% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $101.14 (analyst consensus (n=7)) — fundamentals + valuation re-rating. 5 yr $148.08 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $219.67 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.